HURA News
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) TechnologyPR NewswireTAMPA, Fla., Oct...
PR Newswire
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) TechnologyPR NewswireTAMPA, Fla., Oct...
PR Newswire
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the...
PR Newswire
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire TAMPA, Fla., Sept. 8, 2026 TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc...
PR Newswire
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update PR Newswire TAMPA, Fla., Aug. 14, 2026 TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences...
PR Newswire
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference PR Newswire TAMPA, Fla., July 22, 2026 TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or...
PR Newswire
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting...
PR Newswire
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR...
PR Newswire
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference PR...
PR Newswire
TuHURA Biosciences (NASDAQ:HURA) Earns Outperform Rating from Analysts at Citizens Jmp
Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a report on Monday. They issued an "outperform" rating and a $9.00 price objective for the company...
MarketBeat
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen
Wall Street Zen lowered shares of TuHURA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat